Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expected to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Annual Report”) in the near term.
Full Year 2022 Financial Guidance (GAAP)
The Company reiterates the full year 2022 financial guidance initially announced on February 28, 2022 as set forth below:
Amount ($ in millions) | |
Total revenues (1) | $640 - $680 |
Combined R&D and SG&A expenses | $460 - $490 |
Operating earnings (2) | $20 - $40 |
Effective tax rate | 25% - 28% |
___________________________________________
(1) Includes net product sales and royalty revenue.
(2) Includes amortization of intangible assets and contingent consideration expense (gain).
Full Year 2022 Financial Guidance — GAAP to Non-GAAP Adjustments
An itemized reconciliation between projected operating earnings on a GAAP basis and projected operating earnings on a non-GAAP basis is as follows:
Amount ($ in millions) | |
Operating earnings - GAAP | $20 - $40 |
Adjustments: | |
Amortization of intangible assets | $80 - $85 |
Share-based compensation | $20 - $25 |
Contingent consideration | $8 - $12 |
Depreciation | $2 - $3 |
Operating earnings - non-GAAP | $130 - $165 |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.